Nwam LLC Regeneron Pharmaceuticals, Inc. Transaction History

Nwam LLC

$1.22 Billion
Q1 2024

A detailed history of Nwam LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Nwam LLC holds 1,633 shares of REGN stock, worth $1.75 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

1,633

Previous 1,639 0.37%

Holding current value

$1.75 Million

Previous $1.44 Million 9.17%

% of portfolio

0.13%

Previous 0.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$902.69 - $993.35 $5,416 - $5,960	-6 Reduced 0.37%	1,633 $1.57 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $104,649 - $119,029	-135 Reduced 7.61%	1,639 $1.44 Million
Q3 2023 Oct 31, 2023	BUY	$692.45 - $844.37 $5,539 - $6,754	8 Added 0.45%	1,774 $1.46 Million
Q2 2023 Aug 09, 2023	BUY	$700.03 - $830.35 $98,704 - $117,079	141 Added 8.68%	1,766 $1.27 Million
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $76,214 - $92,620	-112 Reduced 6.45%	1,625 $1.34 Million

Q4 2022 Feb 07, 2023	BUY	$705.89 - $766.39 $75,530 - $82,003	107 Added 6.56%	1,737 $1.25 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $9,757 - $12,313	17 Added 1.05%	1,630 $1.12 Million
Q2 2022 Aug 10, 2022	SELL	$548.35 - $738.84 $220,436 - $297,013	-402 Reduced 19.95%	1,613 $961,000
Q1 2022 May 12, 2022	BUY	$595.12 - $698.43 $15,473 - $18,159	26 Added 1.31%	2,015 $1.41 Million
Q4 2021 Feb 10, 2022	BUY	$543.48 - $670.97 $620,110 - $765,576	1,141 Added 134.55%	1,989 $1.26 Million
Q3 2021 Nov 03, 2021	BUY	$574.03 - $680.96 $486,777 - $577,454	848 New	848 $513,000

Others Institutions Holding REGN

# of Institutions

1,430

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $115B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nwam LLC with notifications on news.

Account